Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
Marinus Pharmaceuticals, Inc. (MRNS) will be presenting at the TD Cowen 44th Annual Healthcare Conference and the Leerink Partners 2024 Global Biopharma Conference in March. The company is dedicated to developing innovative therapeutics for seizure disorders.
02/21/2024 - 07:00 AM
RADNOR, Pa. --(BUSINESS WIRE)--
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present at and participate in the following conferences in March.
The TD Cowen 44th Annual Healthcare Conference in Boston, MA
Panel Discussion: Orphan Epilepsies - March 6 at 10:30 a.m. E.T.
Leerink Partners 2024 Global Biopharma Conference in Miami, FL
Presentation - March 11 at 4:00 p.m. E.T.
Links to the events can be accessed on the Investors and Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations . A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 90 days.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022 and continues to invest in the potential of ganaxolone in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information about Marinus visit www.marinuspharma.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221704060/en/
Investors
jdenike@marinuspharma.com
Media
mcameron@marinuspharma.com
Source: Marinus Pharmaceuticals
When will Marinus Pharmaceuticals present at the TD Cowen 44th Annual Healthcare Conference?
Marinus Pharmaceuticals will present at the TD Cowen 44th Annual Healthcare Conference on March 6 at 10:30 a.m. E.T.
Which conference will Marinus Pharmaceuticals participate in on March 11?
Marinus Pharmaceuticals will participate in the Leerink Partners 2024 Global Biopharma Conference on March 11 at 4:00 p.m. E.T.
Where can links to the events be accessed?
Links to the events can be accessed on the Investors and Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations.
Will there be a replay of the webcast available?
Yes, a replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 90 days.
Marinus Pharmaceuticals Inc
MRNS Rankings
#1099 Ranked by Stock Gains
MRNS Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
About MRNS
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
